ArticleIJTLD open2025
Optimising child-friendly TB preventive treatment regimens.
Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization recommends rifamycin-based TB preventive treatment (TPT) for children, but factors influencing regimen acceptability are not well understood. We explored perceptions of two short-course regimens - 3HP (weekly dosing) and 3RH (daily dosing) - among interest-holders in Ethiopia.
methodsForty-seven in-depth interviews were conducted with caregivers of TB-exposed children, community health workers, health care providers, and policymakers following the CHIP-TB trial, which evaluated home-based TPT delivery. Thematic content analysis was used to assess acceptability across factors such as palatability, dosing frequency, pill burden, adherence, and side effects.
resultsBoth regimens were generally well tolerated. Caregivers reported good palatability, though some children vomited or spit out the medication. Weekly dosing with 3HP was seen as less burdensome but easier to forget, requiring additional support for adherence. Daily 3RH was considered more difficult due to the routine burden on caregivers. Interest-holders preferred 3HP overall but noted concerns about the high number of pills per dose. Mild side effects were reported with both regimens but did not result in discontinuation.
conclusionInterest-holders favoured 3HP for its lower dosing burden, despite concerns about pill burden. Child-friendly, fixed-dose formulations and consideration of caregiver and child preferences are essential to improving adherence and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.